Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Virios Therapeutics, Inc. VIRI NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
23/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Virios Therapeutics, Inc. (VIRI) is a Biotechnology company in the Healthcare sector, currently trading at $0.16. It has a SharesGrow Score of 21/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Net income is $36M (loss), growing at -157550.9%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $75M equity (Debt-to-Equity (D/E) ratio 0, conservative). Debt-to-assets is 0%. Total assets: $90M.

Analyst outlook: 0 / 1 analysts rate VIRI as buy (0%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 28/100 (Fail), Future 20/100 (Fail), Income ?/100 (Fail).

VIRI SharesGrow Score Overview

28/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 20/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — VIRI

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
VIRI: +0%/yr revenue is, -157550.9%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet VIRI: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is N/A. Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
VIRI: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
20/100
Analyst outlook: 0 / 1 analysts rate VIRI as buy (0%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.143-26.0
Volume42.36M
Avg Volume (30D)87.79K
Market Cap$206.5K
Beta (1Y)1.58
Share Statistics
EPS (TTM)-7.13
Shares Outstanding$4.98M
IPO Date2020-12-17
Employees4
CEOGregory Duncan
Financial Highlights & Ratios
EBITDA$-27.97M
Net Income$-35.51M
Operating Income$-27.97B
Total Cash$6.52M
Net Debt$-6.52M
Total Assets$90.17M
Price / Earnings (P/E)-0
Analyst Forecast
Rating ConsensusHold
Analysts Covering1
Buy 0% Hold 100% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS92829J1043

Price Chart

Track all markets on TradingView
VIRI
Virios Therapeutics, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.14 52WK RANGE 26.00

People Also View

IMMX
IMMX
Immix Biopharma, Inc.
$9.85
+1.65%
 ZURA
ZURA
Zura Bio Limited
$5.72
+0.70%
 PHIO
PHIO
Phio Pharmaceuticals Corp.
$1.29
+4.03%
 ICU
ICU
SeaStar Medical Holding Corporation
$3.75
-10.93%
 SONN
SONN
Sonnet BioTherapeutics Holdings, Inc.
$1.26
-59.35%
 RNAZ
RNAZ
TransCode Therapeutics, Inc.
$8.90
+1.14%
 REVB
REVB
Revelation Biosciences, Inc.
$1.20
+0.84%
 ZVSA
ZVSA
ZyVersa Therapeutics, Inc.
$0.19
-8.57%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message